OBJECTIVES: Ovarian stimulation has become a key component of assisted reproductive technologies (ART) and in vitro fertilization (IVF) aims to achieve cost-effective, patient-friendly regimens which optimize the balance between outcomes and risks. The use of ART in Ukraine is approved by the Decree of MOH No.787 dated 09.09.2013. Our aim was to analyze the average cost of gonadotropin treatment use in short stimulation protocol for one cycle of ovarian stimulation from patients’ perspective, based on the real-life practice in the specialized reproductive center in Ukraine.  METHODS: The average direct costs of gonadotropins per cycle were calculated from individual data, multiplying the cost of a single IU by the weighted means of IU used per cycle. We used the weighted average prices from Morion company database (Ukraine) on 01.12.2015 (1 USD = 23,3 UAH). RESULTS: The short protocol is evaluated in 90% of all cases. We have been revealed the use of human-derived follicle-stimulating hormones (HP-hFSH) and recombinant FSH (rFSH) in the physicians’ prescribing practice. Clinical efficacy of HP-hFSH versus recombinant rFSH in IVF cycles has long been compared, but no clear evidence of the superiority of preparation over the other has been found. It has been calculated that the average cost  for HP-hFSH and rFSH in short stimulation protocol  ranged  from $650 to $1082,7 per one cycle for woman.   CONCLUSIONS: The cost of one cycle of ovarian stimulation with HP-hFSH (urofollitropin, menotrophin) is on 23,4% lower versus rFSH – follitropin beta and on 40% lower versus rFSH follitropin alfa. In Ukraine due to the unstable economic situation and out-of-pocket expenditures for medicines, the use of HP-hFSH in the ovarian stimulation protocols is economically beneficial.